The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
There has been a therapeutic revolution in lung cancer. According to the American Lung Association, survival increased by 26% between 2019 and 2024. This progress is largely driven by emerging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results